Reversal by levodopa of cholinergic hypersensitivity in Parkinson's disease.
D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004342:Drug Hypersensitivity; D005260:Female; D006236:Handwriting; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D009461:Neurologic Manifestations; D009474:Neurons / Q000187:drug effects; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000494:pharmacology*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010830:Physostigmine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D013268:Stimulation, Chemical; D014282:Trihexyphenidyl / Q000494:pharmacology; D014326:Tropanes / Q000494:pharmacology
D010276:Parasympatholytics; D010277:Parasympathomimetics; D014326:Tropanes; D004295:Dihydroxyphenylalanine; D014282:Trihexyphenidyl; D010830:Physostigmine; D004298:Dopamine